TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01210001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching BI 10773 high dose
Study: NCT00397579
Drug: DT388IL3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
Study: NCT00544414
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005988
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005988
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005988
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00544414
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05845996
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous/subcutaneous injection
Study: NCT00280267
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02531984
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04424901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose while hospitalized up to 9 days
Study: NCT01133873
Drug: Propoxyphene napsylate (XP20C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
Study: NCT01133873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 times a day in ascending doses until a maximum tolerated dose is identified
Study: NCT02349165
Drug: Ricrolin TE
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
Study: NCT01631864
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 was provided as 400 mg tablets.
Study: NCT01631864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to LCZ696 and amlodipine.
Study: NCT03164603
Drug: NLG802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
Study: NCT01398384
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MI size at 48-72 hours
Study: NCT01038570
Drug: Syntocinon®/- Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sprays corresponding to 24 IU in each nostril
Study: NCT03805269
Drug: wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: wound infiltration: local anesthetics infiltration at surgical incision
Study: NCT03619252
Drug: Standard Antibacterial Prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
Study: NCT01501942
Drug: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
Study: NCT01501942
Drug: Buffered Saline
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo is an oral solution of phosphate buffered saline
Study: NCT03926052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
Study: NCT02134756
Drug: NutraStem Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01580878
Drug: Lotrimin Ultra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
Study: NCT03868137
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of Ibuprofen 800 mg
Study: NCT03868137
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02701634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT02655237
Drug: Leuprorelin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin placebo-matching injections
Study: NCT04068532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04068532
Drug: BIIB104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02280629
Drug: LT-02
Normalized name: LT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
Study: NCT02280629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
Study: NCT01572792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose-matched placebo, twice per day
Study: NCT03399526
Drug: Calcipotriene 0.005% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
Study: NCT00269048
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01375101
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient is directed to use placebo capsule two times a day, ,until the one mouth
Study: NCT02543411
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol
Study: NCT00757601
Drug: MK1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Study: NCT00757601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose
Study: NCT03089112
Drug: HGP1607
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT03089112
Drug: HGP1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT02856178
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
Study: NCT03089112
Drug: HGP1607+HGP1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once per period
Study: NCT04362085
Drug: Therapeutic Anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study: NCT00144391
Drug: Transdermal Testosterone gel
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
Study: NCT03656432
Drug: CPP-ACP paste
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
Study: NCT01122771
Drug: liposomal amphotericin B + paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Study: NCT01122771
Drug: Miltefosine + Paromomycin
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Study: NCT02585765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of daily placebo capsules.
Study: NCT02753114
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Normal Saline administered via mucosal atomization device.
Study: NCT00783237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, single dose of 2 sprays per nostril
Study: NCT02419105
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal gel, 75 mg daily
Study: NCT02419105
Drug: Placebo drink solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: drink solution, 0 IU Colecalciferol once per month
Study: NCT02419105
Drug: Placebo transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal gel, 0 mg testosterone daily
Study: NCT01721993
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02211079
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
Study: NCT01673217
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02138682
Drug: l-123 Ioflupane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 millicuries of Ioflupane
Study: NCT04626505
Drug: Placebo (ziltivekimab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered s.c. once every 4 weeks for 12 weeks
Study: NCT00102908
Drug: Zoledronate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate placebo infusion
Study: NCT03925480
Drug: Azithromycin 500 mg Oral Tablet x 4
Normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single prophylactic dose of antibiotic given during labour
Study: NCT03925480
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00067236
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, twice a day for 90 days
Study: NCT01098721
Drug: WBI-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
Study: NCT00297401
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO, up to 8 weeks
Study: NCT02607072
Drug: Acetylsalicylic acid (ASA)/aspirin 200 mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607072
Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00726700
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00726700
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02715947
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
Study: NCT00920140
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
Study: NCT00920140
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be maximum tolerated dose based on Phase I results.
Study: NCT01770964
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03100500
Drug: QMF149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
Study: NCT01466153
Drug: MEDI-551
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Study: NCT01021189
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
Study: NCT01021189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution Dose single and followed by 7-day multiple dosing.
Study: NCT00492869
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02143648
Drug: Placebo tablets BID
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets BID administered for 8 weeks
Study: NCT00404313
Drug: MK0633
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
Study: NCT00404313
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
Study: NCT03153657
Drug: Piroxicam-Beta-Cyclodextrin
Normalized name: piroxicam-beta-cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
Study: NCT02099175
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2/day - Powder for solution for infusion
Study: NCT02998567
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: In arm B2 (lung expansion) replacing guadecitabine
Study: NCT03153657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
Study: NCT01074710
Drug: [2-13C] uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: po, in the form of semi-solid meal, granules, once a period
Study: NCT01074710
Drug: [2-13C] uracil, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po, in the form of semi-solid meal, granules, once a period
Study: NCT01202591
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet oral twice daily
Study: NCT01202591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet oral twice daily
Study: NCT01278849
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00300274
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids standard dose.
Study: NCT03372044
Drug: PF-06865571 Slow release MR tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tablets
Study: NCT00148915
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00148915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01170650
Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
Normalized name: doxorubicin hydrochloride liposome Injection [Caelyx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
Study: NCT01170650
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Study: NCT01456117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone matching placebo once daily for up to 14 days.
Study: NCT04665947
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
Study: NCT00442910
Drug: 3% SPL7013 Gel (VivaGel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% vaginal gel
Study: NCT00442910
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for SPL7013 gel
Study: NCT00442910
Drug: HEC Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC Placebo gel intravaginally bd for 14 days
Study: NCT03862248
Drug: 6EH³RZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
Study: NCT03862248
Drug: 6EHR³Z
Approvals — FDA: no, EMA: no, PMDA: no
Description: New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
Study: NCT03862248
Drug: 6EHRZLfx
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO levofloxacin-strengthened regimen (6EHRZLfx)
Study: NCT05084456
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Study: NCT03239522
Drug: [14C]-GSK1278863 solution for IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
Study: NCT03239522
Drug: [14C]-GSK1278863 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
Study: NCT02468739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
Study: NCT00929539
Drug: JTT-130 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT01423370
Drug: YHD1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g oral once daily
Study: NCT01423370
Drug: YHD1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g oral twice a day
Study: NCT01423370
Drug: YHD1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g oral once daily
Study: NCT01423370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00134459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02742441
Drug: 122-0551 Foam
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Foam containing active drug
Study: NCT02709902
Drug: EPIDUO® FORTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT02468674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study: NCT03712956
Drug: Caelyx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caelyx® every two weeks for 8 courses
Study: NCT03980041
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally in 28-day cycles
Study: NCT02709902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT00583609
Drug: PEG3350
Normalized name: PEG3350
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG3350
Study: NCT00560235
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
Study: NCT03991975
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT00732290
Drug: Clopidogrel then fluoxetine+clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
Study: NCT02576600
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI
Study: NCT02939391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04218695
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50cc intravenous once daily
Study: NCT00234741
Drug: STA-5326 mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00094172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet form
Study: NCT00002734
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02821169
Drug: saline solution 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach